CB₂: therapeutic target-in-waiting

Area of Science:

• Pharmacology
• Drug Discovery
• Immunology

Background:

• Cannabinoid receptor 2 (CB₂) agonists are investigated for diverse therapeutic applications including pain, neuroinflammation, immune suppression, and osteoporosis.
• Preclinical data strongly support the potential of CB₂ agonists across various models.
• Clinical trial outcomes for CB₂ agonists have generally been disappointing, contrasting with preclinical findings.

Purpose of the Study:

• To explore reasons for the discrepancy between promising preclinical results and disappointing clinical outcomes for CB₂ agonists.
• To propose that a deeper understanding of CB₂ receptor pharmacology is crucial for advancing CB₂ agonists.
• To bridge the gap between the potential of CB₂ agonists and their successful clinical application.

Main Methods:

• Review of existing preclinical and clinical data on CB₂ agonists.
• Analysis of pharmacological properties and their implications.
• Identification of potential factors contributing to clinical trial failures.

Main Results:

• Significant promise for CB₂ agonists in preclinical studies across multiple therapeutic areas.
• Consistent disappointment in reported clinical trials for CB₂ agonists.
• A notable gap exists between in vitro/in vivo efficacy and human clinical response.

Conclusions:

• A critical re-evaluation of CB₂ receptor pharmacology is necessary to optimize therapeutic strategies.
• Understanding nuanced receptor interactions may unlock the full potential of CB₂ agonists.
• Further research into CB₂ pharmacology could translate promising preclinical data into effective clinical treatments.